GlassScriptPhysician profile
Caroline Digiacomo
NPI 1922646215
$4,705.64
in general payments reported to CMS, 2019-2025
45 companies · $577 in 2025
The $577 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,007 · 2022: $1,345 · 2023: $549 · 2024: $1,228 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $599.83 | 2021-2025 | |
| Ucb, INC. | $344.11 | 2021-2024 | Briviact, Rystiggo |
| Novartis Pharmaceuticals Corporation | $320.27 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $312.13 | 2022-2025 | Nuplazid |
| Sumitomo Pharma America, INC. | $254.60 | 2023-2024 | Aptiom |
| Teva Pharmaceuticals USA, INC. | $236.98 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $233.69 | 2021-2025 | Vumerity, Tysabri, Plegridy |
| Lilly USA, LLC | $208.21 | 2021-2024 | Emgality, Kisunla, Amyvid |
| Biohaven Pharmaceuticals, INC. | $199.42 | 2021 | |
| Sunovion Pharmaceuticals INC. | $166.75 | 2021-2022 | |
| Lundbeck LLC | $149.50 | 2021-2025 | Rexulti, Vyepti |
| Upsher-Smith Laboratories LLC | $146.25 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $144.98 | 2021-2024 | Ultomiris, Soliris |
| Kyowa Kirin, INC. | $126.00 | 2021-2022 | |
| Neurelis, INC. | $104.81 | 2022-2024 | Valtoco |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Digiacomo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.